news
pharma& is a rapidly growing, internationally oriented company in a very exciting moment of expansion. In this section of the website, we regularly share our news with you.
31/10/2022
pharma& Schweiz GmbH (“pharma&”) is proud to announce to have acquired all of the remaining rights of Farydak® (Panobinostat) from Secura Bio to secure long-term demand for a well-established therapy option used for the treatment of multiple myeloma.
31/01/2022
We are proud to announce that we closed an agreement with Astellas Deutschland GmbH, (a subsidiary of Astellas Pharma Inc.) on December 31st 2021 to acquire Astellas’ worldwide rights* of Bendamustine commercialized under the brand names Levact®, Ribomustin® and others, securing access and continuous supply for patients benefitting from this well-established and distinguished therapy option.
For any inquiries, please contact us at contact@pharmaand.com.
*) excluding Marketing Authorizations in a small number of markets, including Morocco which is subject to merger clearance.
read more in our news archive